The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial
This study is the first to assess the perioperative time course of systemic inflammation and
immunity in colon cancer patients and evaluate the effect of anti-inflammatory treatment
with celecoxib on this response. In addition, evaluation of the effect of short-term
preoperative administration of celecoxib on tumor immunogenicity will help us to understand
how tumor-enhancing inflammation and anti-tumor immunity can be differentially affected by
COX-2 inhibitors. The knowledge gained as a result of this research will help us to set up
the infrastructure for a method to monitor the immunoinflammatory status of colon cancer
patients with a longer term goal of designing interventions to suppress tumor-enhancing
inflammation and vitalize anti-tumor immunity in the perioperative period. The long-term
objective is to use these novel tools in order to improve cancer-specific survival in
patients with colon cancer after primary tumor resection.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Tumor sample - Analyzed for TCR Repertoire and Global Transcription Profiling
2 years
No
Anthony Doufas
Principal Investigator
Stanford University
United States: Institutional Review Board
COL0001
NCT01284504
January 2011
May 2011
Name | Location |
---|---|
Stanford University School of Medicine | Stanford, California 94305-5317 |